$28.60
-0.46-1.58%
Last update: Nov 11, 4:00 PM
Amphastar Pharmaceuticals Inc
AMPHNASDAQ
Amphastar Pharmaceuticals rose 5.3% from $27.16 to $28.60, behind the S&P 500's +9.8%. Its worst day was Feb 27 (−23.6%), and its low came May 15 at $16.87.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Amphastar Pharmaceuticals closed at its highest level of the year, 8.2% above where the year started.
+6.0% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
EPS of $0.73 missed the $0.91 estimate on $183.1M revenue (est. $191.7M).
−23.6%, the year's worst day · S&P 500 −0.5%
EPS of $0.42 missed the $0.69 estimate on $171.2M revenue (est. $172.9M).
−20.9%, on 2M shares, the year's heaviest volume · S&P 500 +0.8%
EPS of $0.91 beat the $0.62 estimate on $183.9M revenue (est. $180.4M).
+4.9% · S&P 500 +0.6%
EPS of $1.14 beat the $0.85 estimate on $207.6M revenue (est. $196.9M).
+3.0% · S&P 500 +0.3%
Where it ended: a close of $28.60 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.69, revenue est. $193.3M).
Nothing in the past 12 months.
All AMPH dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AMPH and SPY from Benzinga historical bars. Not investment advice.
